Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Clinical Trials
172
Active:23
Completed:34
Trial Phases
5 Phases
Phase 1:64
Phase 2:29
Phase 3:40
+2 more phases
Drug Approvals
26
FDA:20
CANADA:2
PHILIPPINES:2
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (163 trials with phase data)• Click on a phase to view related trials
Phase 1
64 (39.3%)Phase 3
40 (24.5%)Phase 2
29 (17.8%)Not Applicable
28 (17.2%)Phase 4
2 (1.2%)A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Prostate Cancer
- Interventions
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 212
- Registration Number
- NCT07198633
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Not Applicable
Not yet recruiting
- Conditions
- Relapsed or Refractory Hematologic Malignancies
- Interventions
- Drug: QLS2309
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT07173595
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: QLC1401
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT07173556
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Not Applicable
Not yet recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT07162883
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Not Applicable
Not yet recruiting
- Conditions
- CLDN18.2-positive Advanced Biliary Tract Cancer
- Interventions
- Drug: QLS31905 for InjectionDrug: QL2107 Injection
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT07151872
- Prev
- 1
- 2
- 3
- 4
- 5
- 30
- Next
News
No news found